Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) rose 2.6% to $83.45 on Friday after the company disclosed that the European Commission granted marketing authorization for its obesity treatment Imcivree.
The approval covers treatment of obesity and control of hunger in adults and children aged four and older who have acquired hypothalamic obesity - a rare disorder that arises from injury or damage to the hypothalamus. According to the company announcement, Imcivree is now the first therapy approved in Europe specifically for this condition.
Rhythm noted that Imcivree previously received approval in the United States in March. The company said it intends to begin commercial launches across Europe in 2027, initiating country-by-country access applications ahead of those rollouts.
Despite Friday's positive reaction, the stock remains lower on the year. Including the day’s gain, Rhythm's shares have declined 22.3% year to date.
Context and implications
Regulatory clearance in Europe establishes a new treatment option for a narrowly defined patient population affected by acquired hypothalamic obesity. As the first authorized drug for the condition on the continent, Imcivree could alter treatment pathways for these patients, subject to national access decisions and commercial rollout timing.
The company's plan to pursue country-by-country access applications indicates that market entry will be phased rather than simultaneous across all European markets - a process that can affect timing of patient access and revenue realization.
Key points
- European Commission approved Imcivree for adults and children aged four and older with acquired hypothalamic obesity.
- Imcivree is the first treatment authorized in Europe for this rare hypothalamic injury-related disorder.
- Rhythm plans commercial launches in Europe in 2027, pursuing access on a country-by-country basis - sectors affected include biotechnology and healthcare markets.
Risks and uncertainties
- Rollout timing and patient access will depend on the outcome and pace of country-by-country applications across European markets, which could delay or stagger commercial availability.
- The condition targeted by Imcivree is described as rare, which could constrain the size of the addressable patient population and affect market uptake.
- Rhythm’s share price remains under pressure year to date, with a 22.3% decline including the recent gain, reflecting market sensitivity to execution and commercial progress.
Conclusion
The European approval of Imcivree is a regulatory milestone for Rhythm Pharmaceuticals and a potential new option for patients with acquired hypothalamic obesity. Commercialization in Europe is planned for 2027, but access and timing will hinge on national applications and approvals. Investors and market participants in the biotech and healthcare sectors will likely monitor Rhythm’s progress as the company moves toward phased launches and broader patient access.